A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants
Clinical trial NCT02290340 · COMPLETED
Trial details
- NCT number
- NCT02290340
- Sponsor
- MedImmune LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-01-13
- Primary completion
- 2016-09-28
- Enrollment
- 151
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.